SAN DIEGO—During ACR Convergence 2023 on Nov. 11, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2023 Awards of Distinction, as well as the 2023 ACR Masters who were recognized for their contributions to the field.
SAN DIEGO—Each year, the ACR honors up to 10 clinical and research fellows who have performed meritoriously. Meet this year’s Distinguished Fellows who are bridging the gap between research and patient care and who were recognized at ACR Convergence 2023 in November.
SAN DIEGO—Recognition as an ACR Master is one of the highest honors the College bestows. This year, the ACR conferred the honor on 25 distinguished rheumatologists.
SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.
SAN DIEGO—Award presentations & artificial intelligence topped the list in the ACR Convergence 2023 Opening Session & Keynote Lecture on Nov. 11.
Some people may think Pakistan and Oklahoma share little in common, but one recent graduate of the rheumatology fellowship program at Louisiana State University, Shreveport (LSUS), School of Medicine disagrees. Iman Qaiser, MD, MBBS, a native of Pakistan who is starting a role as the only rheumatologist serving the Choctaw Nation of Oklahoma, sees natural…
Pneumatosis cystoides intestinalis (PCI) is a rare gastrointestinal pathological process defined by the presence of gas within the layers of the intestinal wall, commonly within the mucosa and submucosa of the small and large intestines.2,3 PCI has been described in the literature in association with various connective tissue diseases, including scleroderma, mixed connective tissue disease,…
A pediatric rheumatologist diagnosed with RA following the birth of her first child talks about integrative care & offers tips for helping patients reduce the symptom burden.
This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.
Canakinumab has received FDA approval for the treatment of patients with acute gout flares.